Chimeric Therapeutics Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net income was AUD 2.44 million compared to net loss of AUD 11.75 million a year ago. Basic earnings per share from continuing operations was AUD 0.0044 compared to basic loss per share from continuing operations of AUD 0.0275 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.019 AUD | +5.56% | -13.64% | -45.71% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.71% | 10.31M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.12% | 21.96B | |
-9.28% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CHM Stock
- News Chimeric Therapeutics Limited
- Chimeric Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023